ECHONCT05051722
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
At risk: Primary completion moved at least 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 31, 2026 to Jul 30, 2027
- Study completion pushed from Jun 30, 2027 to Sep 30, 2027
- Study sites revised (25)
- Notable Eligibility criteria expanded, about 85 words
- Study sites: 24 to 25
- Minor Site details revised at 12 of 24 sitesv18
- Minor Study sites: 20 to 24
- Primary completion date: Oct 31, 2026 to Dec 31, 2026
- Study completion date: Dec 30, 2026 to Jun 30, 2027
- Minor Study sites: 18 to 20
- Primary completion date: Jun 30, 2026 to Oct 31, 2026
Show 12 earlier versionsHide 12 earlier versions
Notable Primary completion date: Dec 31, 2025 to Jun 30, 2026v14 Show 7 more changesShow less
- Eligibility criteria expanded, about 46 words
- Primary endpoints revised (2)
- Enrollment target: 2640 to 3110
- Study completion date: Jun 30, 2026 to Dec 30, 2026
- Interventions: Blood Collection (Diagnostic Test), Tampon Collection (Diagnostic Test) to Blood Collection (Diagnostic Test), Vaginal Fluid Collection (Diagnostic Test)
- Secondary endpoint revised
- Site details revised at 6 of 18 sites
- Minor Study sites: 17 to 18
- Primary completion date: Oct 31, 2025 to Dec 31, 2025
- Study completion date: Dec 30, 2025 to Jun 30, 2026
- Minor Study sites: 15 to 17
- Primary completion date: Jun 30, 2025 to Oct 31, 2025
- Minor Study sites: 12 to 15v11
- Notable Primary completion date: Dec 31, 2024 to Jun 30, 2025
- Study sites: 10 to 12
- Study completion date: Mar 30, 2025 to Dec 30, 2025
- Minor Study sites: 9 to 10v9
- Minor Study sites: 7 to 9v8
- Minor Study sites: 6 to 7v7
- Minor Study sites: 3 to 6v6
- Notable Primary completion date: Dec 31, 2023 to Dec 31, 2024
- Study completion date: Mar 30, 2024 to Mar 30, 2025
- Site details revised at 1 of 3 sites
Notable Eligibility criteria expanded, about 310 wordsv4 Show 9 more changesShow less
- Primary endpoints: 1 to 2
- Enrollment target: 1776 to 2640
- Study sites: 1 to 3
- Primary completion date: Oct 2023 to Dec 31, 2023
- Study completion date: Dec 2023 to Mar 30, 2024
- Start date: Jul 30, 2021 to Aug 3, 2021
- Study arms: 5 to 7
- Study description expanded, about 1 word
- Study title expanded, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Sep 2021 to Jul 30, 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Patients ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). Patients ages 18 - 44 years of age, presenting with abnormal uterine bleeding (AUB) and a risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
Patients ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
Patients ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
Patients with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All patients enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
Healthy patients with a uterus, ≥45 years of age presenting for GYN wellness exam to serve as a control group. These patients will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These patients will not have known or clinically suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
Patients ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients may have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC.
Patients ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment.
Diagnostic tests: Vaginal Fluid Collection, Blood Collection
Sites
25 sites in 1 country